The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human PUS3 (UniProt Q9BZE2) — functional annotation, mechanism, localization, and disease relevance

1) Key concepts, definitions, and current understanding

Gene/protein identity and enzymatic class. Human PUS3 (UniProt Q9BZE2) encodes a stand-alone pseudouridine synthase in the TruA family (tRNA pseudouridine synthases). Its primary biochemical role is to catalyze isomerization of uridine (U) to pseudouridine (Ψ) in RNA (EC 5.4.99.45), a covalent rearrangement that changes the glycosidic linkage from N–C to C–C and introduces an N1-H capable of additional hydrogen bonding, typically increasing RNA structural stability. This role and family assignment are consistent across biochemical and review sources focused on human PUS3. (lin2022destabilizationofmutated pages 2-2, guillenangel2024exploringpseudouridylationdysregulation pages 1-3)

Primary functional annotation (reaction and site). The highest-confidence, PUS3-specific reaction is installation of Ψ in the tRNA anticodon stem–loop, particularly positions 38/39 (often discussed as Ψ38/Ψ39). A primary biochemical study using recombinant human PUS3 shows direct catalysis of tRNA Ψ39 formation in vitro using CMC-based primer extension assays. (lin2022destabilizationofmutated pages 13-13, lin2022destabilizationofmutated pages 10-10)

Substrate specificity. Mechanistic synthesis of recent work indicates that human PUS3 has strict selectivity for intact, tRNA-shaped substrates (recognizing global tRNA architecture) and does not bind isolated anticodon stem-loop fragments efficiently. In transcriptome-wide analyses summarized in a mechanistic review, Pseudo-seq in PUS3-depleted human cells found no PUS3-dependent pseudouridylation sites in mRNAs, supporting that PUS3’s primary substrates are tRNAs rather than mRNAs. (lin2025mechanisticinsightinto pages 4-5)

Important nuance (mRNA targets). Some reviews and summary tables list PUS3 among enzymes that can target tRNA and mRNA, but this is not consistently supported by the mechanistic evidence available in the retrieved corpus; accordingly, direct human mRNA targeting by PUS3 should be treated as lower-confidence than the tRNA anticodon-loop activity. (guillenangel2024exploringpseudouridylationdysregulation pages 1-3, lin2025mechanisticinsightinto pages 4-5)

2) Recent developments and latest research (prioritizing 2023–2024)

2024 disease-focused pseudouridylation synthesis. A 2024 review on pseudouridylation dysregulation and therapeutic potential explicitly lists PUS3 among human pseudouridine synthases whose mutations are associated with neurodevelopmental disease, and notes reported RNA substrates as tRNA and mRNA at the level of review compilation. It further highlights overlapping clinical phenotypes across PUS3/PUS7-related disorders (developmental delay, microcephaly, intellectual disability, speech delay, facial dysmorphism). (Guillen-Angel & Roignant, Curr Opin Genet Dev, Aug 2024; https://doi.org/10.1016/j.gde.2024.102210) (guillenangel2024exploringpseudouridylationdysregulation pages 1-3)

2024 translation-to-disease framing. A 2024 clinical genetics synthesis of PUS3-associated neurodevelopmental disorder (from earlier literature) is complemented by mechanistic work (below) that emphasizes how loss of PUS3-dependent Ψ39 can plausibly perturb translation programs; in yeast, absence of Ψ38/Ψ39 in tRNA is linked to altered stop-codon readthrough and frameshifting. While yeast results cannot be directly assumed for humans, they strengthen the conceptual link between anticodon-loop Ψ and decoding behavior. (rintaladempsey2017eukaryoticstandalonepseudouridine pages 8-11)

Key mechanistic advance (not 2023–2024 but foundational for current understanding). A pivotal mechanistic study (2022) established that certain disease-associated PUS3 missense variants can cause disease not by abolishing catalytic activity in vitro, but by destabilizing/aggregating the enzyme, thereby reducing cellular protein levels and lowering PUS3-dependent tRNA Ψ levels in patient cells. This “protein stability/abundance” disease mechanism is now a central interpretation in the field. (Lin et al., Human Mutation, Oct 2022; https://doi.org/10.1002/humu.24471) (lin2022destabilizationofmutated pages 1-2, lin2022destabilizationofmutated pages 13-13)

3) Current applications and real-world implementations

Clinical genetics/diagnostics. The principal real-world application of PUS3 knowledge is variant interpretation in neurodevelopmental disorders. A major cohort study compiled 21 individuals from 15 families with biallelic PUS3 variants and delineated the phenotypic spectrum, enabling gene-panel inclusion for developmental delay, epilepsy, and microcephaly evaluations. (Nøstvik et al., Clinical Genetics, Aug 2021; https://doi.org/10.1111/cge.14051) (nøstvik2021clinicalandmolecular pages 2-3)

Functional validation workflows. Lin et al. (2022) provides a concrete translational pipeline used in practice for rare-disease mechanism: recombinant enzyme biochemistry (binding and Ψ installation assays), plus patient fibroblast assays demonstrating reduced PUS3 protein and reduced PUS3-dependent Ψ39. Such assays can support ACMG/AMP functional evidence frameworks, although clinical labs may rely on curated knowledge and phenotypic concordance rather than custom enzyme assays. (lin2022destabilizationofmutated pages 10-10, lin2022destabilizationofmutated pages 1-2)

Therapeutic implications (emerging, not yet PUS3-specific). The 2024 review frames pseudouridylation as therapeutically interesting (e.g., because Ψ can influence RNA stability/translation), but no PUS3-targeted therapy or clinical trials were identified in the retrieved evidence. Thus, “implementation” remains primarily diagnostic and mechanistic rather than interventional. (guillenangel2024exploringpseudouridylationdysregulation pages 1-3)

4) Expert opinions and authoritative analyses

Consensus view: PUS enzymes are broader regulators, but PUS3 is primarily a tRNA writer. A widely cited review of stand-alone pseudouridine synthases argues that these enzymes may influence gene expression more broadly than previously appreciated, including via regulated pseudouridylation patterns. For Pus3 family enzymes, the review emphasizes the functional consequences of anticodon-loop Ψ38/Ψ39 on translation recoding in yeast and discusses potential for additional targets, reflecting the field’s historical expansion from “tRNA-only” to “multi-RNA” thinking. (Rintala-Dempsey & Kothe, RNA Biology, 2017; https://doi.org/10.1080/15476286.2016.1276150) (rintaladempsey2017eukaryoticstandalonepseudouridine pages 8-11)

Updated mechanistic perspective: stringent substrate architecture requirement and limited mRNA evidence. A mechanistic synthesis of pseudouridylation emphasizes PUS3’s dimeric architecture and its requirement for intact tRNA structure, and reports that PUS3 depletion did not reveal detectable PUS3-dependent Ψ sites in mRNAs by Pseudo-seq, tempering earlier broad “mRNA target” expectations for PUS3 specifically. (Lin et al., RNA Biology, 2025; https://doi.org/10.1080/15476286.2025.2541421) (lin2025mechanisticinsightinto pages 4-5)

5) Key statistics and quantitative data

5.1 Biochemical/biophysical measurements (human PUS3)

tRNA binding affinity (MST EC50). Recombinant PUS3 binds tRNA with micromolar affinity; reported EC50 values are 3.7 ± 0.6 μM (WT) and 2.6 ± 0.7 μM (Y71C), consistent with the interpretation that Y71C does not strongly impair tRNA binding in vitro. (Lin et al., 2022) (lin2022destabilizationofmutated media 50e21fba)

Protein thermal stability (Tm). PUS3 Y71C substantially reduces protein stability, with Tm 40.1 ± 0.1 °C, compared with WT 51.4 ± 0.1 °C (and catalytic-dead D118A 52.8 ± 0.1 °C), supporting a destabilization mechanism. (Lin et al., 2022) (lin2022destabilizationofmutated media 50e21fba)

Cellular Ψ39 dependence and patient-cell reduction. Patient-derived fibroblasts with disease-associated variants show reduced PUS3 protein levels and reduced PUS3-dependent Ψ39 signal by CMC-based primer extension assay, linking genotype → lower enzyme abundance → lower tRNA Ψ39. (Lin et al., 2022) (lin2022destabilizationofmutated pages 1-2, lin2022destabilizationofmutated media 01f1d012)

5.2 Clinical cohort statistics (PUS3-associated neurodevelopmental disorder)

From a 21-individual cohort: epilepsy 13/18 (72%), brain MRI abnormalities 11/15 (73%), microcephaly/anencephaly 13/18 (72%), facial dysmorphism 17/18 (94%), with short stature frequently observed (≤3rd percentile in multiple individuals), and 17 distinct variants across variant classes (missense and truncating among others). (Nøstvik et al., 2021) (nøstvik2021clinicalandmolecular pages 2-3)

5.3 Population genetics and database-level statistics

Population frequency example. A recurrent variant p.Tyr71Cys is reported with a population allele frequency of 0.0001 in Europeans (gnomAD exome, as cited in the study). (lin2022destabilizationofmutated pages 13-13)

Open Targets association metrics. Open Targets reports evidence-supported associations of PUS3 with intellectual disability and microcephaly with evidence size = 5 for each and association scores around 0.37 in the retrieved output, consistent with published clinical genetics evidence. (OpenTargets Search: -PUS3)

Evidence synthesis table

Table: This table summarizes the strongest functional annotation evidence for human PUS3/Q9BZE2 across biochemistry, mechanism, localization, pathway context, and human disease. It is useful for quickly separating high-confidence claims (tRNA Ψ38/39 catalysis, neurodevelopmental disorder association) from less-settled points such as direct human mRNA targeting.

Integrated functional annotation (narrative)

Enzymatic function and substrate specificity

Human PUS3 is best annotated as a tRNA anticodon-loop pseudouridine synthase producing Ψ38/Ψ39, with primary biochemical evidence for Ψ39 installation on multiple tRNAs in vitro. (lin2022destabilizationofmutated pages 13-13, lin2022destabilizationofmutated pages 10-10) Mechanistically, available synthesis indicates that PUS3 recognizes overall tRNA architecture—consistent with a dimeric binding mode—and does not efficiently act on isolated ASL fragments, suggesting that specificity is dominated by shape/tertiary-structure recognition plus local anticodon-stem positioning of the target uridine. (lin2025mechanisticinsightinto pages 4-5)

Subcellular localization

Within the retrieved evidence set, PUS3 is reported as present in nucleus and cytoplasm, consistent with roles spanning nuclear pre-tRNA processing/maturation and cytoplasmic function of modified tRNAs. No retrieved evidence supported mitochondrial localization for human PUS3. (yang2025pseudouridinesynthase7 pages 2-4)

Pathway context and biological roles

PUS3 functions in tRNA modification and biogenesis. Anticodon-loop pseudouridylation has translation-recoding implications in yeast (stop-codon readthrough and +1 frameshifts), providing a plausible mechanistic bridge to human neurodevelopmental phenotypes when tRNA modification is impaired—though direct demonstration of altered readthrough/frameshifting in human PUS3 deficiency remains to be established in the retrieved corpus. (rintaladempsey2017eukaryoticstandalonepseudouridine pages 8-11)

Human disease mechanism

Biallelic PUS3 variants cause a neurodevelopmental disorder whose core features include intellectual disability/developmental delay, frequent epilepsy, microcephaly, hypotonia, and variable MRI abnormalities. (nøstvik2021clinicalandmolecular pages 2-3) A key mechanistic insight is that at least some missense variants act via protein destabilization/aggregation, leading to decreased PUS3 protein abundance in patient cells and reduced PUS3-dependent tRNA Ψ39, rather than by eliminating catalytic competence in purified in vitro assays. (lin2022destabilizationofmutated pages 1-2, lin2022destabilizationofmutated media 50e21fba, lin2022destabilizationofmutated media 01f1d012)

Key sources (with URLs and publication dates)

1. Lin T-Y et al. “Destabilization of mutated human PUS3 protein causes intellectual disability.” Human Mutation (Oct 2022). https://doi.org/10.1002/humu.24471 (lin2022destabilizationofmutated pages 1-2, lin2022destabilizationofmutated media 50e21fba, lin2022destabilizationofmutated media 01f1d012)
2. Nøstvik M et al. “Clinical and molecular delineation of PUS3-associated neurodevelopmental disorders.” Clinical Genetics (Aug 2021). https://doi.org/10.1111/cge.14051 (nøstvik2021clinicalandmolecular pages 2-3)
3. Guillen-Angel M, Roignant J-Y. “Exploring pseudouridylation: dysregulation in disease and therapeutic potential.” Current Opinion in Genetics & Development (Aug 2024). https://doi.org/10.1016/j.gde.2024.102210 (guillenangel2024exploringpseudouridylationdysregulation pages 1-3)
4. Rintala-Dempsey AC, Kothe U. “Eukaryotic stand-alone pseudouridine synthases – RNA modifying enzymes and emerging regulators of gene expression?” RNA Biology (Feb 2017). https://doi.org/10.1080/15476286.2016.1276150 (rintaladempsey2017eukaryoticstandalonepseudouridine pages 8-11)
5. Lin T-Y et al. “Mechanistic insight into the pseudouridylation of RNA.” RNA Biology (2025). https://doi.org/10.1080/15476286.2025.2541421 (lin2025mechanisticinsightinto pages 4-5)
6. Open Targets Platform: PUS3 disease associations (tool-retrieved evidence; includes linked PMIDs). (OpenTargets Search: -PUS3)

Figures supporting key quantitative claims (primary evidence)

Panels extracted from Lin et al. (2022) include quantitative EC50 values for tRNA binding and Tm for WT vs mutant PUS3, and patient-fibroblast assays demonstrating reduced PUS3-dependent Ψ39. (lin2022destabilizationofmutated media 50e21fba, lin2022destabilizationofmutated media 01f1d012, lin2022destabilizationofmutated media 98202f2d)

References

1. (lin2022destabilizationofmutated pages 2-2): Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, Andrzej Chramiec‐Głąbik, Jakub Jeżowski, Jakub Nowak, Monika Gos, Sylwia Rzonca‐Niewczas, Magdalena Dziembowska, Rafał Ploski, and Sebastian Glatt. Destabilization of mutated human pus3 protein causes intellectual disability. Human Mutation, 43:2063-2078, Oct 2022. URL: https://doi.org/10.1002/humu.24471, doi:10.1002/humu.24471. This article has 26 citations and is from a domain leading peer-reviewed journal.

2. (guillenangel2024exploringpseudouridylationdysregulation pages 1-3): Maria Guillen-Angel and Jean-Yves Roignant. Exploring pseudouridylation: dysregulation in disease and therapeutic potential. Aug 2024. URL: https://doi.org/10.1016/j.gde.2024.102210, doi:10.1016/j.gde.2024.102210. This article has 18 citations and is from a peer-reviewed journal.

3. (lin2022destabilizationofmutated pages 13-13): Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, Andrzej Chramiec‐Głąbik, Jakub Jeżowski, Jakub Nowak, Monika Gos, Sylwia Rzonca‐Niewczas, Magdalena Dziembowska, Rafał Ploski, and Sebastian Glatt. Destabilization of mutated human pus3 protein causes intellectual disability. Human Mutation, 43:2063-2078, Oct 2022. URL: https://doi.org/10.1002/humu.24471, doi:10.1002/humu.24471. This article has 26 citations and is from a domain leading peer-reviewed journal.

4. (lin2022destabilizationofmutated pages 10-10): Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, Andrzej Chramiec‐Głąbik, Jakub Jeżowski, Jakub Nowak, Monika Gos, Sylwia Rzonca‐Niewczas, Magdalena Dziembowska, Rafał Ploski, and Sebastian Glatt. Destabilization of mutated human pus3 protein causes intellectual disability. Human Mutation, 43:2063-2078, Oct 2022. URL: https://doi.org/10.1002/humu.24471, doi:10.1002/humu.24471. This article has 26 citations and is from a domain leading peer-reviewed journal.

5. (lin2025mechanisticinsightinto pages 4-5): Ting-Yu Lin, Yasmin Stone, and Sebastian Glatt. Mechanistic insight into the pseudouridylation of rna. RNA biology, 22 1:1-25, 2025. URL: https://doi.org/10.1080/15476286.2025.2541421, doi:10.1080/15476286.2025.2541421. This article has 5 citations and is from a peer-reviewed journal.

6. (rintaladempsey2017eukaryoticstandalonepseudouridine pages 8-11): Anne C. Rintala-Dempsey and Ute Kothe. Eukaryotic stand-alone pseudouridine synthases – rna modifying enzymes and emerging regulators of gene expression? RNA Biology, 14:1185-1196, Feb 2017. URL: https://doi.org/10.1080/15476286.2016.1276150, doi:10.1080/15476286.2016.1276150. This article has 214 citations and is from a peer-reviewed journal.

7. (lin2022destabilizationofmutated pages 1-2): Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, Andrzej Chramiec‐Głąbik, Jakub Jeżowski, Jakub Nowak, Monika Gos, Sylwia Rzonca‐Niewczas, Magdalena Dziembowska, Rafał Ploski, and Sebastian Glatt. Destabilization of mutated human pus3 protein causes intellectual disability. Human Mutation, 43:2063-2078, Oct 2022. URL: https://doi.org/10.1002/humu.24471, doi:10.1002/humu.24471. This article has 26 citations and is from a domain leading peer-reviewed journal.

8. (nøstvik2021clinicalandmolecular pages 2-3): Miriam Nøstvik, Sarah M. Kateta, Bitten Schönewolf‐Greulich, Alexandra Afenjar, Magalie Barth, Felix Boschann, Diane Doummar, Tobias B. Haack, Boris Keren, Ludmila A. Livshits, Davide Mei, Joohyun Park, Tiziana Pisano, Clement Prouteau, Muhammad Umair, Ahmed Waqas, Alban Ziegler, Renzo Guerrini, Rikke S. Møller, and Zeynep Tümer. Clinical and molecular delineation of pus3‐associated neurodevelopmental disorders. Clinical Genetics, 100:628-633, Aug 2021. URL: https://doi.org/10.1111/cge.14051, doi:10.1111/cge.14051. This article has 37 citations and is from a peer-reviewed journal.

9. (lin2022destabilizationofmutated media 50e21fba): Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, Andrzej Chramiec‐Głąbik, Jakub Jeżowski, Jakub Nowak, Monika Gos, Sylwia Rzonca‐Niewczas, Magdalena Dziembowska, Rafał Ploski, and Sebastian Glatt. Destabilization of mutated human pus3 protein causes intellectual disability. Human Mutation, 43:2063-2078, Oct 2022. URL: https://doi.org/10.1002/humu.24471, doi:10.1002/humu.24471. This article has 26 citations and is from a domain leading peer-reviewed journal.

10. (lin2022destabilizationofmutated media 01f1d012): Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, Andrzej Chramiec‐Głąbik, Jakub Jeżowski, Jakub Nowak, Monika Gos, Sylwia Rzonca‐Niewczas, Magdalena Dziembowska, Rafał Ploski, and Sebastian Glatt. Destabilization of mutated human pus3 protein causes intellectual disability. Human Mutation, 43:2063-2078, Oct 2022. URL: https://doi.org/10.1002/humu.24471, doi:10.1002/humu.24471. This article has 26 citations and is from a domain leading peer-reviewed journal.

11. (OpenTargets Search: -PUS3): Open Targets Query (-PUS3, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

12. (yang2025pseudouridinesynthase7 pages 2-4): Qiwei Yang, Thomas G. Boyer, and Ayman Al-Hendy. Pseudouridine synthase 7 in cancer: functions, mechanisms, and therapeutic potential. Cells, 14:1380, Sep 2025. URL: https://doi.org/10.3390/cells14171380, doi:10.3390/cells14171380. This article has 7 citations.

13. (lin2022destabilizationofmutated media 98202f2d): Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, Andrzej Chramiec‐Głąbik, Jakub Jeżowski, Jakub Nowak, Monika Gos, Sylwia Rzonca‐Niewczas, Magdalena Dziembowska, Rafał Ploski, and Sebastian Glatt. Destabilization of mutated human pus3 protein causes intellectual disability. Human Mutation, 43:2063-2078, Oct 2022. URL: https://doi.org/10.1002/humu.24471, doi:10.1002/humu.24471. This article has 26 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
  

Citations

1. lin2025mechanisticinsightinto pages 4-5
2. guillenangel2024exploringpseudouridylationdysregulation pages 1-3
3. rintaladempsey2017eukaryoticstandalonepseudouridine pages 8-11
4. lin2022destabilizationofmutated pages 13-13
5. lin2022destabilizationofmutated pages 2-2
6. lin2022destabilizationofmutated pages 10-10
7. lin2022destabilizationofmutated pages 1-2
8. https://doi.org/10.1016/j.gde.2024.102210
9. https://doi.org/10.1002/humu.24471
10. https://doi.org/10.1111/cge.14051
11. https://doi.org/10.1080/15476286.2016.1276150
12. https://doi.org/10.1080/15476286.2025.2541421
13. https://doi.org/10.1002/humu.24471;
14. https://doi.org/10.1080/15476286.2025.2541421;
15. https://doi.org/10.3390/cells14171380
16. https://doi.org/10.1111/cge.14051;
17. https://doi.org/10.1016/j.gde.2024.102210;
18. https://doi.org/10.1002/humu.24471,
19. https://doi.org/10.1016/j.gde.2024.102210,
20. https://doi.org/10.1080/15476286.2025.2541421,
21. https://doi.org/10.1080/15476286.2016.1276150,
22. https://doi.org/10.1111/cge.14051,
23. https://doi.org/10.3390/cells14171380,

Deep Research Report: PUS3 (human)

Generated using OpenAI Deep Research API

PUS3 (Human) Comprehensive Gene Annotation Report

Gene Function and Molecular Mechanisms

PUS3 (pseudouridine synthase 3) encodes an enzyme responsible for the post-transcriptional modification of transfer RNA (tRNA) by isomerizing specific uridine bases to pseudouridine (www.ncbi.nlm.nih.gov). In particular, human PUS3 catalyzes the formation of pseudouridine at position 39 (and position 38 in some tRNAs) within the anticodon stem-loop of cytosolic tRNAs (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Pseudouridine (Ψ) is the C5-glycoside isomer of uridine and is the most abundant RNA modification, found in tRNA, rRNA, snRNA, and even mRNA (pmc.ncbi.nlm.nih.gov). The enzymatic reaction involves cleavage of the N1–C1′ glycosidic bond of uridine and rotation of the base before reattachment to form pseudouridine (pmc.ncbi.nlm.nih.gov). Like other pseudouridine synthases, PUS3 acts as an RNA isomerase (EC 5.4.99.45) that does not require cofactors, instead using a conserved aspartate residue in the active site to catalyze the isomerization via a glycal intermediate (pmc.ncbi.nlm.nih.gov). This reaction introduces an additional imino hydrogen (at N1) on the nucleoside, enhancing RNA stability and base-pairing capacity (pmc.ncbi.nlm.nih.gov) (pseudouridine can form an extra hydrogen bond), which in tRNAs helps stabilize the anticodon loop structure (pmc.ncbi.nlm.nih.gov). Consistent with this molecular role, patient cells lacking functional PUS3 have significantly reduced pseudouridine levels in their tRNAs (pmc.ncbi.nlm.nih.gov), underscoring the enzyme’s importance in maintaining normal tRNA structure and function.

PUS3 is a “stand-alone” pseudouridine synthase, meaning it autonomously binds its RNA substrate without requiring a guide RNA or larger ribonucleoprotein complex (pmc.ncbi.nlm.nih.gov). It belongs to the TruA family of pseudouridine synthases (also known as the Pus3 family in eukaryotes), which generally target uridines in the anticodon arm of tRNAs (pmc.ncbi.nlm.nih.gov). Members of this family share a conserved catalytic mechanism and core fold across all domains of life (pmc.ncbi.nlm.nih.gov). Human PUS3 specifically modifies a broad subset of cytosolic tRNAs at the anticodon loop, introducing Ψ at position 38 and/or 39 depending on the tRNA (pmc.ncbi.nlm.nih.gov). This modification is critical for proper tRNA folding and decoding function during translation. Indeed, pseudouridylation of the anticodon loop has been shown to stabilize tRNA structure and can influence codon recognition fidelity (pmc.ncbi.nlm.nih.gov). Notably, PUS3 activity appears specific to tRNAs; recent high-throughput mapping found no PUS3-dependent pseudouridine sites in mRNAs, linking the enzyme’s function exclusively to tRNA modification and the associated disease phenotype to tRNA defects (pmc.ncbi.nlm.nih.gov).

Cellular Localization and Subcellular Components

PUS3 predominantly localizes to the nucleus and the cytoplasm, consistent with its role in modifying tRNAs which are transcribed and processed in the nucleus and function in the cytosol (www.genecards.org) (www.genecards.org). UniProt curators annotate PUS3 as a nuclear protein (www.genecards.org), and Gene Ontology likewise indicates PUS3 is active in the nucleus (GO:0005634) and cytoplasm (GO:0005737) (www.genecards.org). Experimental data from the Human Protein Atlas confirm PUS3 presence in the nucleoplasm and cytosol of human cells (www.genecards.org). The enzyme likely acts on nascent or nuclear pre-tRNAs prior to their export, consistent with many tRNA modification processes occurring co-transcriptionally or during tRNA maturation in the nucleus. PUS3 may also remain associated with tRNAs in the cytosol, given its detection in that compartment (www.genecards.org). The COMPARTMENTS database (integrating multiple localization evidence) likewise scores PUS3 highest for the cytosol and nucleus (confidence scores 5 and 4, respectively) (www.genecards.org). There is minimal evidence of PUS3 in other organelles (e.g. trace association with mitochondrion or ER scored as very low confidence) (www.genecards.org), aligning with the understanding that PUS3 acts on cytosolic (nuclear-encoded) tRNAs, and not on mitochondrial tRNAs (mitochondrial tRNA pseudouridylation is performed by distinct enzymes such as PUS1). Overall, PUS3 is a soluble, non-membrane protein functioning in the nucleocytoplasmic compartment to ensure tRNAs acquire proper pseudouridine modifications.

Biological Processes Involvement

As a tRNA pseudouridine synthase, PUS3 is directly involved in tRNA processing and RNA post-transcriptional modification pathways. Gene Ontology classifies PUS3 in the biological process of “tRNA processing” (GO:0008033), reflecting its role in the maturation of tRNA molecules (www.proteinatlas.org). The specific reaction catalyzed by PUS3 – addition of pseudouridine at the anticodon loop – is a type of tRNA base modification (tRNA pseudouridylation), a sub-process essential for generating functional tRNAs. By catalyzing pseudouridine formation at key positions, PUS3 contributes to the proper folding of tRNAs and stabilization of the anticodon stem-loop (pmc.ncbi.nlm.nih.gov). This, in turn, impacts translation efficiency and fidelity, as modifications in the anticodon loop can influence codon–anticodon interactions and ribosome binding. Indeed, pseudouridine in tRNA has been shown to stabilize codon-anticodon pairing and support accurate reading of the mRNA codon (pmc.ncbi.nlm.nih.gov). Thus, PUS3’s activity is tied to the broader biological process of protein synthesis, ensuring the translational machinery has a pool of correctly modified tRNAs.

Importantly, proper tRNA modification has emerged as critical for certain tissue functions, especially the brain. The discovery that PUS3 mutations cause neurological disease highlights the biological process of neurodevelopment being indirectly affected by tRNA modification (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). The brain appears particularly sensitive to disruptions in tRNA modifications, as evidenced by severe intellectual disability resulting from PUS3 loss of function (pmc.ncbi.nlm.nih.gov). While PUS3’s immediate role is at the molecular level (tRNA maturation), the downstream biological processes influenced include neuronal development, cognitive function, and cellular growth. In model organisms, pseudouridine synthases of the PUS3/TruA family are important for healthy growth and viability (pmc.ncbi.nlm.nih.gov), indicating that the pseudouridylation of tRNAs is fundamental for normal cell physiology. In summary, PUS3 is involved in:

• tRNA modification – specifically pseudouridine formation in tRNAs (pmc.ncbi.nlm.nih.gov).
• tRNA processing and maturation as part of RNA post-transcriptional modification pathways (GO:0008033) (www.proteinatlas.org).
• Translation – by ensuring tRNAs are properly modified for efficient protein synthesis.
• Neurodevelopment and cell viability – as an indirect consequence of its role in maintaining the translation machinery; defects lead to developmental abnormalities (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

Disease Associations and Phenotypes

Biallelic pathogenic variants in PUS3 cause a rare autosomal recessive neurodevelopmental disorder. This condition is designated “Neurodevelopmental Disorder with Microcephaly and Gray Sclerae” (NEDMIGS), also known as Mental Retardation, autosomal recessive 55 (MRT55) in older nomenclature (www.genecards.org) (www.genecards.org). The syndrome is characterized by severe global developmental delays and profound intellectual disability, often accompanied by hypotonia (poor muscle tone) and markedly impaired speech or absent language development (www.genecards.org). Affected children frequently present with microcephaly (small head/brain size) that can be mild to moderate, and many exhibit seizures/epilepsy starting in infancy or childhood (www.genecards.org) (pubmed.ncbi.nlm.nih.gov). A distinctive but variably present feature is gray sclerae, referring to abnormal bluish-gray coloration of the whites of the eyes due to underlying connective tissue differences (www.genecards.org). This ocular finding, along with other pigmentary anomalies such as extensive dermal melanocytosis (bluish skin patches), was noted in the original cases and gives the disorder its name (www.genecards.org).

Beyond the core neurological phenotype, multisystem developmental abnormalities have been reported in some patients with PUS3 mutations. Common associated features include short stature or growth deficiency, and variable dysmorphic facial features (pubmed.ncbi.nlm.nih.gov). Some individuals have had ocular and retinal anomalies (e.g. retinal dystrophy or visual impairment) and strabismus, indicating that eye development can be affected (pubmed.ncbi.nlm.nih.gov) (www.genecards.org). Structural brain changes such as cerebellar hypoplasia have been observed via neuroimaging in at least one case (pubmed.ncbi.nlm.nih.gov), although many patients have unremarkable brain MRI despite severe clinical deficits (www.ncbi.nlm.nih.gov). Outside the nervous system, there are occasional reports of congenital malformations: for example, a child with a truncating PUS3 mutation was described with a congenital heart defect and kidney hypoplasia in addition to microcephaly and retinal degeneration (pubmed.ncbi.nlm.nih.gov). However, these visceral anomalies are less consistently seen and might represent the more severe end of the spectrum. Overall, the consistent phenotype of PUS3 deficiency is an intellectual disability syndrome with microcephaly, seizures, hypotonia, and growth failure, sometimes accompanied by unique features like grey/blue sclerae and skin melanocytosis (www.genecards.org) (www.genecards.org).

At the cellular level, patient-derived cells (such as fibroblasts) show loss of PUS3 enzyme activity, evidenced by reduced pseudouridine content in tRNA (pmc.ncbi.nlm.nih.gov). The consequences of this at the molecular level likely include destabilization of certain tRNAs and translational dysregulation, which are hypothesized to particularly impact rapidly developing tissues like the brain (pmc.ncbi.nlm.nih.gov). Consistent with this, PUS3-related disorder is one of several recently recognized tRNA modification syndromes, where perturbation of tRNA modifications leads to neurodevelopmental disease (pmc.ncbi.nlm.nih.gov). There is no known association of PUS3 with cancer or adult-onset disorders; the phenotypes manifest early in development due to the gene’s crucial role in basic cellular processes.

Protein Domains and Structural Features

The PUS3 protein is composed of 481 amino acids and contains a conserved pseudouridine synthase core flanked by unique extensions. Domain architecture analyses and structural studies indicate that human PUS3 has a central TruA-like core domain (the pseudouridine synthase catalytic domain) that is highly conserved among pseudouridine synthases (pmc.ncbi.nlm.nih.gov). This core domain contains the active site and the signature fold of the TruA/PseudoU synthase family – an α/β fold with a conserved catalytic aspartate residue that performs nucleophilic attack on the uridine base (pmc.ncbi.nlm.nih.gov). Flanking this core, PUS3 possesses eukaryote-specific N-terminal and C-terminal extensions that are absent in simpler bacterial homologs (pmc.ncbi.nlm.nih.gov). The N-terminal region (approximately residues 1–65) includes a segment annotated as DUF3373 (domain of unknown function) (www.ncbi.nlm.nih.gov). Although termed a DUF, this segment is thought to contribute to RNA-binding specificity or stability of the enzyme. The C-terminal region (residues ~338–481) is notably important for the protein’s quaternary structure: it forms a long α-helix (around amino acids 338–369) that mediates homodimerization of PUS3 (pmc.ncbi.nlm.nih.gov). Two PUS3 monomers interact via this parallel coiled-coil helical motif, assembling into a homodimeric complex (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Dimerization is a conserved feature of TruA family pseudouridine synthases (for example, E. coli TruA is a dimer), and is required for full activity – likely positioning two active sites in proper orientation to modify uridines 38 and 39 on a tRNA simultaneously or to stabilize tRNA binding.

Structural analyses (including a recent high-resolution cryo-EM structure of human PUS3) confirm that the core domain harbors the catalytic cleft and RNA-binding surfaces, while the flexible terminal extensions enhance substrate selectivity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The PUS3 dimer presents an extended RNA-binding interface, accommodating the L-shaped tRNA substrate. Notably, the C-terminal coiled-coil appears to be a unique adaptation in higher eukaryotes: sequence comparisons show this helical region is conserved in mammalian PUS3 orthologs, whereas bacterial TruA enzymes lack a comparable C-terminal helix (pmc.ncbi.nlm.nih.gov). The coiled-coil likely stabilizes the dimer or positions the C-termini for optimal tRNA interaction. In contrast, the N-terminal extension (DUF3373) in PUS3 might assist in recognizing specific tRNA features; for example, eukaryotic PUS3 enzymes may use their N-terminus to differentiate subsets of tRNAs, a property under investigation in recent studies.

In summary, PUS3 is a monomer of ~54 kDa that forms a functional dimer (~108 kDa). Each subunit contains: (1) an N-terminal region (unique to eukaryotes) of ~60 amino acids, (2) a pseudouridine synthase core domain (~Residues 70–330) that carries out catalysis (www.ncbi.nlm.nih.gov), and (3) a C-terminal α-helical extension (~Residues 338–481) that mediates dimerization and possibly additional RNA contacts (pmc.ncbi.nlm.nih.gov). The protein’s active site includes the invariant aspartate (by homology, human PUS3’s catalytic Asp is at position 118, as evidenced by mutagenesis studies where D118A abolishes activity) – this Asp residue is necessary for forming the covalent enzyme–RNA intermediate during catalysis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Together, these structural features enable PUS3 to specifically bind tRNA and catalyze pseudouridine formation with high precision. The InterPro/Pfam classification groups PUS3 in the PseudoU_synth_1 family (Pfam PF01416), reflecting its membership in the pseudouridine synthase I family that also includes E. coli TruA (www.rcsb.org).

Expression Patterns and Regulation

Baseline Expression: PUS3 is expressed ubiquitously in human tissues, consistent with its role in a fundamental cellular process (tRNA modification). RNA expression profiling (e.g. GTEx data) indicates that PUS3 mRNA is present in all examined tissues, with moderate expression levels. For instance, the gene shows an RPKM of ~5 in adult liver and ~3.5 in appendix, with broadly similar expression in at least 25 other tissues (www.ncbi.nlm.nih.gov). This suggests PUS3 is a housekeeping gene, required in most cell types for normal protein synthesis. The Human Protein Atlas likewise classifies PUS3 as expressed in all surveyed tissues (RNA tissue category: “Expressed in all”), and it has evidence at the protein level (www.proteinatlas.org). There may be some variation in expression levels: proteomic analyses (HIPED) reported PUS3 protein to be relatively high in heart tissue and adipocytes compared to other tissues (www.genecards.org), though the functional significance of this is not fully clear. Generally, tissues with high rates of protein synthesis or high metabolic activity (such as brain, muscle, heart) would have a greater demand for correctly modified tRNAs, which could explain higher PUS3 expression in those contexts.

Developmental and Cell-Type Expression: During development, PUS3 is also widely expressed. Data from LifeMap indicate PUS3 transcripts are present in embryonic tissues including the developing brain, pituitary gland, gastrointestinal tract (foregut), and eye (retina) (www.genecards.org). This broad developmental expression aligns with the wide-ranging phenotype of PUS3 deficiency (affecting multiple organs). Notably, PUS3 expression in neural tissues (brain) during development supports the idea that sufficient PUS3 activity is critical for neurodevelopment. In cellular systems, PUS3 mRNA and protein have been detected in numerous cell lines; no cell-type specific isoforms or highly restricted expression have been reported. Immunocytochemistry confirms a nucleocytosolic distribution in diverse cell types (www.genecards.org).

Regulation: Currently, there is limited information on specific transcriptional or post-transcriptional regulation of the PUS3 gene. No dedicated transcription factors or regulatory elements unique to PUS3 have been well-characterized. The GeneHancer database does list some candidate promoter/enhancer elements near the PUS3 locus (www.genecards.org), but their functional impact is unverified. Given its ubiquitous expression, PUS3 is likely controlled by general housekeeping gene promoters. There is no evidence that PUS3 is strongly inducible or regulated by stress conditions (unlike some tRNA-modifying enzymes that respond to nutrient stress, although this has not been shown for PUS3). In patient cells, remaining wild-type allele expression (in carriers) appears sufficient for normal function, and no dominant-negative effects have been observed — consistent with a loss-of-function recessive disease mechanism (www.ncbi.nlm.nih.gov).

Importantly, alternative splicing of PUS3 results in two transcript variants encoding different isoforms (www.ncbi.nlm.nih.gov). The major isoform is the full-length 481-residue protein (corresponding to NM_001272, NP_001258914.1), while a minor isoform (NP_112597.4) may lack a portion of the coding sequence (the exact differences are not fully described in RefSeq but could involve N- or C-terminal truncation). Both isoforms include the core catalytic domain, and their enzymatic activity is presumed to be similar, though the shorter isoform might have altered localization or stability if it lacks part of the regulatory termini. The existence of these isoforms suggests potential regulation at the mRNA splicing level, but the functional significance remains unclear. To date, most studies of PUS3 (and all known pathogenic mutations) pertain to the full-length isoform.

In summary, PUS3 is constitutively expressed in most human cells, providing a steady supply of pseudouridine synthase activity for tRNA modification. Its expression pattern reflects its essential cellular role rather than tissue-specific functions. The gene’s regulation appears to be largely housekeeping in nature, and disease-causing mutations typically reduce or eliminate the functional protein rather than mis-regulate its expression.

Evolutionary Conservation

PUS3 is highly evolutionarily conserved across a wide range of organisms, underscoring its fundamental role in RNA biology. Orthologs of human PUS3 can be found in all eukaryotic lineages, and functionally analogous enzymes exist in bacteria and archaea. In fact, PUS3 belongs to the ancient TruA/Pus3 family of pseudouridine synthases, which is present in all domains of life (pmc.ncbi.nlm.nih.gov). The E. coli truA gene (tRNA pseudouridine synthase I) was one of the first pseudouridine synthases identified; it modifies uridines in the anticodon loop of bacterial tRNAs and is considered the bacterial counterpart of PUS3. Yeast (Saccharomyces cerevisiae) has a PUS3 ortholog known as Deg1 (also called Pus3 in some literature), which carries out the same pseudouridylation on cytosolic tRNAs (www.orpha.net). These yeast and bacterial enzymes share significant sequence motifs with human PUS3, especially in the catalytic domain, indicating a common origin. The catalytic Asp residue and key sequence motifs (such as the consensus sequence around the active site) are conserved from bacteria to humans (pmc.ncbi.nlm.nih.gov).

Functionally, the importance of PUS3 is conserved as well. Loss of the PUS3 ortholog in model organisms leads to growth and developmental defects, highlighting its necessity. For example, E. coli truA mutants lacking pseudouridine at tRNA positions 38/39 exhibit reduced fitness, particularly at higher temperatures or stress conditions (pmc.ncbi.nlm.nih.gov). In S. cerevisiae, deletion of Deg1 is viable but causes cold-sensitive growth phenotypes and defects in tRNA function (pmc.ncbi.nlm.nih.gov). Likewise, mouse Pus3 is nearly identical to human PUS3 in sequence and is expressed in similar patterns, implying a conserved role in mammals (though a mouse knockout phenotype has not been widely reported in literature, one would predict neurological impairments given the human data). The sequence identity between human PUS3 and mouse Pus3 is high (on the order of ~96% amino acid identity (pmc.ncbi.nlm.nih.gov) for the core domain, with divergence mostly in the poorly conserved tail regions), reflecting strong evolutionary pressure to maintain this enzyme’s function.

The eukaryote-specific extensions of PUS3 (N- and C-termini) evolved later and are conserved mainly within higher eukaryotic clades. For instance, mammals share the coiled-coil dimerization helix in the C-terminus (pmc.ncbi.nlm.nih.gov), whereas in fungi and lower eukaryotes this region is shorter or divergent, yet these proteins still form dimers (possibly through an alternate interface). This suggests that while the core enzymatic function is ancient, some regulatory or structural adaptations have occurred in multicellular organisms, potentially to modulate PUS3 activity, stability, or interactions in more complex cellular contexts.

Taken together, the PUS3 gene/protein is evolutionarily conserved from bacteria (TruA) to humans, indicating that pseudouridine formation in tRNA anticodon loops is a universally critical process (pmc.ncbi.nlm.nih.gov). The conservation in sequence and function is so high that cross-species complementation is feasible: a human PUS3 can functionally replace yeast Deg1, for example, to rescue its pseudouridylation function (pmc.ncbi.nlm.nih.gov). This evolutionary preservation highlights that PUS3 performs a fundamental cellular role that has been maintained for billions of years.

Key Experimental Evidence and Literature

Multiple lines of experimental evidence have elucidated PUS3’s function and its link to disease:

• Genetic Discovery (2016): Shaheen et al. (2016) first implicated PUS3 in human disease by identifying a homozygous truncating mutation (Arg435*) in a consanguineous family with syndromic intellectual disability (pmc.ncbi.nlm.nih.gov). They demonstrated that cells from affected individuals had a significant loss of tRNA pseudouridine modifications, consistent with PUS3 loss-of-function (pmc.ncbi.nlm.nih.gov). This study established the connection between PUS3 enzymatic activity and normal cognitive development (pmc.ncbi.nlm.nih.gov). It also highlighted the broader concept that tRNA modification defects can cause neurodevelopmental disorders, as the Arg435 mutation in PUS3 was shown to segregate perfectly with the intellectual disability phenotype (pmc.ncbi.nlm.nih.gov). This foundational finding (OMIM: 617051*) defined a new autosomal recessive ID syndrome caused by PUS3 mutations.

• Phenotypic Expansion (2016–2021): Following the initial report, additional PUS3 variant cases were identified. Froukh et al. (2020) and Nøstvik et al. (2021) described new patients from different populations carrying biallelic PUS3 mutations (including missense and splice-site variants), thereby expanding the phenotypic spectrum (www.genecards.org) (pubmed.ncbi.nlm.nih.gov). These studies confirmed that severe intellectual disability with microcephaly is the consistent outcome of PUS3 loss, while also documenting variable features like seizures, pigmentary abnormalities (gray sclerae), and organ developmental defects (www.genecards.org) (pubmed.ncbi.nlm.nih.gov). For instance, Nøstvik et al. 2021 (Clinical Genetics) compiled clinical data on multiple individuals and helped delineate commonalities (global developmental delay, hypotonia, lack of speech) and variability in PUS3-related neurodevelopmental disorder (www.genecards.org). These works firmly established PUS3 mutations as a recurrent cause of a recognizable syndromic ID condition (sometimes referred to as NEDMIGS or MRT55).

• Biochemical and Cellular Studies (2022): Lin et al. (2022, Human Mutation) investigated the molecular consequences of PUS3 mutations in patient cells and in vitro. They characterized two missense mutations (e.g. Tyr71Cys and Ile299Thr) found in patients and discovered that these mutations lead to protein instability and degradation (www.ncbi.nlm.nih.gov). Fibroblasts from patients showed drastically reduced PUS3 protein levels despite normal mRNA levels, indicating that the mutant proteins were misfolded and turned over by the proteasome (www.ncbi.nlm.nih.gov). In vitro expression and purification experiments echoed this: the Ile299Thr mutant was less stable and prone to aggregation, explaining the loss-of-function at the protein level (www.ncbi.nlm.nih.gov). Moreover, this study directly measured tRNA modifications in patient-derived cells, confirming the absence of PUS3-catalyzed pseudouridines in multiple tRNAs from those patients (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Lin et al. also gathered all known PUS3 variants up to that time and confirmed that all were extremely rare in the general population and segregated with disease in families (www.ncbi.nlm.nih.gov). This provided a clear genotype–phenotype correlation and mechanistic insight: many disease-causing PUS3 alleles produce an unstable enzyme, leading to deficient tRNA pseudouridylation and cellular dysfunction.

• Structural and Mechanistic Insight (2024): The most detailed mechanistic understanding of PUS3 came from a study by Lin et al. (2024, Molecular Cell), in which researchers solved the structure of human PUS3 (including a catalytically inactive mutant D118A) in complex with tRNA substrates. They revealed that PUS3 forms a homodimer and uncovered how it specifically recognizes its tRNA targets (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The structural data, combined with binding assays, showed PUS3’s preferences for certain tRNA sequence/structure features (explaining why it pseudouridinates particular tRNAs at position 39). Notably, they found that PUS3’s C-terminal coiled-coil dimerization domain is crucial for high-affinity tRNA binding and that each PUS3 dimer can potentially engage two tRNA molecules (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, this work confirmed that PUS3 has no off-target activity on other RNA classes (e.g., no pseudouridylation detected in rRNA or mRNA in PUS3-proficient vs deficient cells) (pmc.ncbi.nlm.nih.gov). This comprehensive analysis solidified our understanding of PUS3’s catalytic mechanism, substrate selectivity, and the structural basis for its function. It also provided a framework to interpret how different mutations (e.g. ones affecting the core vs the dimerization helix) impact the enzyme’s function – for example, a mutation in the core active site versus one destabilizing the dimer interface could both abrogate activity.

• Additional References: Earlier fundamental studies on pseudouridine synthases, predating the identification of human PUS3, also inform our knowledge. Biochemical characterization of E. coli TruA and yeast Deg1 had demonstrated the requirement of a particular aspartate and the dimeric nature of these enzymes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Those classical studies, along with more recent reviews (e.g. Charette and Gray 2000 (pmc.ncbi.nlm.nih.gov), Rintala-Dempsey & Kothe 2017), provide context that PUS3 operates via the same conserved mechanism as other pseudouridine synthases. Furthermore, clinical genetics databases (ClinVar, DECIPHER) list several pathogenic PUS3 variants, and model organism databases (MGI for mouse, SGD for yeast) note the phenotype of PUS3/Pus3/Deg1 loss in model systems, reinforcing the human findings.

In conclusion, a robust body of evidence – from human genetics and clinical observations to cellular biochemistry and structural biology – converges to explain PUS3’s role. PUS3 is a tRNA pseudouridine synthase essential for proper neuron development and function, and when this enzyme is absent or nonfunctional, the resulting cascade of tRNA instability and translational impairment leads to a defined neurodevelopmental syndrome. This gene’s annotations in the Gene Ontology and related databases reflect these findings, ensuring that PUS3 is recognized for its RNA-binding, pseudouridine synthase activity and its involvement in tRNA processing and human disease.

Gene Ontology Annotations (Selected Terms)

• Molecular Function:
• RNA binding (GO:0003723) – PUS3 binds tRNA molecules as part of its function (www.genecards.org).
• Pseudouridine synthase activity (GO:0009982) – Catalyzes the isomerization of uridine to pseudouridine in RNA (www.genecards.org).

• Isomerase activity (GO:0016853) – General enzymatic function category for catalyzing intramolecular rearrangements (www.genecards.org).

• Biological Process:

• tRNA processing (GO:0008033) – Involved in the post-transcriptional processing and modification of tRNAs (pseudouridylation is a tRNA processing step) (www.proteinatlas.org).
• tRNA pseudouridine synthesis (GO term specific to pseudouridylation of tRNA; often captured under tRNA modification) – PUS3’s specific role in forming pseudouridine at tRNA position 38/39 (pmc.ncbi.nlm.nih.gov).

• Translation (GO:0006412) (indirectly) – By modifying tRNAs, PUS3 contributes to the fidelity and efficiency of protein translation (this link is inferred from the requirement of proper tRNA function for translation).

• Cellular Component:

• Nucleus (GO:0005634) – PUS3 is active in the nucleus, where initial tRNA modification occurs (www.genecards.org).
• Cytoplasm (GO:0005737) – PUS3 is also present in the cytoplasm, implying it may interact with tRNAs in the cytosol as well (www.genecards.org).
• Cytosol (GO:0005829) – Detected in the cytosolic fraction of cells (www.genecards.org).

Each of these GO annotations is supported by experimental or sequence-homology evidence (e.g., EXP: experiment, IBA: inferred from biological ancestor, TAS: author statement) from the literature and curation databases (www.genecards.org) (www.genecards.org). These terms collectively summarize PUS3’s role as an RNA-binding isomerase (pseudouridine synthase) that operates in the nucleus/cytosol on tRNA substrates, and they align with the phenotypic consequences observed when the gene is disrupted.